Official title and information are available only for Plus and Premium subscribers.
Patent Granted Survivin is known to be highly expressed in most tumour cell types and absent in normal cells, making it a good target for cancer therapy.[15][16][17][18][19] The exploitation of survivin's over-active promoter in most cancer cell types allows for the delivery of therapeutics only in cancer cells and removed from normal cells.
To see the additional information details please login and subscribe to a Plus or Premium account.
